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Abstract
Background: Hypovitaminosis D has been recently recognized as a worldwide epidemic. Since vitamin D exerts
significant metabolic activities, comprising free fatty acids (FFA) flux regulation from the periphery to the liver, its
deficiency may promote fat deposition into the hepatocytes. Aim of our study was to test the hypothesis of a
direct association between hypovitaminosis D and the presence of NAFLD in subjects with various degree of
insulin-resistance and related metabolic disorders.
Methods: We studied 262 consecutive subjects referred to the Diabetes and Metabolic Diseases clinics for
metabolic evaluation. NAFLD (non-alcoholic fatty liver disease) was diagnosed by upper abdomen ultrasonography,
metabolic syndrome was identified according to the Third Report of National Cholesterol Education Program/Adult
Treatment Panel (NCEP/ATPIII) modified criteria. Insulin-resistance was evaluated by means of HOMA-IR. Fatty-Liver-
Index, a recently identified correlate of NAFLD, was also estimated. Serum 25(OH)vitamin D was measured by
colorimetric method.
Results: Patients with NAFLD (n = 162,61.8%) had reduced serum 25(OH) vitamin D levels compared to subjects
without NAFLD (14.8 ± 9.2 vs 20.5 ± 9.7 ng/ml, p < 0.001, OR 0.95, IC 95% 0.92-0.98). The relationship between
NAFLD and reduced 25(OH)vitamin D levels was independent from age, sex, triglycerides, high density lipoproteins
(HDL) and glycaemia (p < 0.005) and Fatty Liver Index inversely correlated with low 25(OH) vitamin D regardless
sex, age and HOMA-IR (p < 0.007).
Conclusions: Low 25(OH)vitamin D levels are associated with the presence of NAFLD independently from
metabolic syndrome, diabetes and insulin-resistance profile.
Background
Vitamin D is a lipophilic molecule essential to calcium
and phosphate balance and osteo-metabolic system reg-
ulation. It is produced onto the skin through a UV-
mediated reaction, then it is metabolized to its active
1a,25 (OH)2 form through two consecutive hydroxyla-
tions exerted by kidney and liver, respectively. In adult
population, the prevalence of hypovitaminosis D is from
5% to 30% [1], but it reaches a peak of 75% in patients
with metabolic syndrome (MS) [2]. Several evidences
have shown a thigh link between serum vitamin D level,
calcium homeostasis and the risk for cardiovascular dis-
ease [3,4]. Interestingly, vitamin D deficient individuals
are more likely to develop alterations in glucose metabo-
lism, such as impaired glucose tolerance, the metabolic
syndrome and type 2 diabetes mellitus [5-7]. Based on
these evidences, it can be hypothesized that vitamin D
deficiency should not be considered an exclusive feature
of patients with osteo-mineral disorders. Vitamin D is
capable to reduce FFA-induced insulin resistance both
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low serum vitamin D may predispose to intrahepatic
lipid accumulation leading to NAFLD.
NAFLD is a pathological condition consisting in a
spectrum of liver diseases due to macrovesicular accu-
mulation of triglycerides within hepatocytes (hepatic
steatosis). In developed countries, NAFLD is observed in
20-30% of the general population [9,10] and in 75% of
type 2 diabetic patients [11,12]; necro-inflammatory
activity and fibrosis coexist in the 2-3% of cases (non-
alcoholic steatohepatitis, NASH) and may evolve in cir-
rhosis and liver failure in 20-25% of affected subjects
[13-15]. Currently, NAFLD is considered one of the
leading causes of cryptogenetic cirrhosis [16].
Recently, an increased risk of cardiovascular disease in
patients with NAFLD has been also suggested [17],
based on the strong association between NAFLD and
MS [18].
Thus, NAFLD is historically considered the hepatic
component of MS, attributable to insulin-resistance that
increases NEFA (non-esterified fatty acids) release from
adipose tissue into the bloodstream and favors their
deposition into hepatocytes [19]. However, recent inves-
tigations hypothesized a primary role of fatty liver in
determining insulin resistance and its consequences
[20]. Therefore, aim of this study was to test the
hypothesis of an association between hypovitaminosis D
and the presence/degree of NAFLD.
Methods
Population under study
To these purposes, we studied 262 consecutive subjects
referred to the Diabetes and Hepatology outpatient
clinics of Sapienza University of Rome for suspected
MS. To be eligible for the study, patients had to fulfil
the following criteria: normal serum liver enzymes, no
history of current or past excessive alcohol drinking as
defined by an average daily consumption of alcohol < 30
g/die in men and < 20 g/die in women; negative tests
for the presence of hepatitis B surface antigen and anti-
body to hepatitis C virus; absence of history and find-
ings consistent with cirrhosis and other chronic liver
diseases. All subjects had a complete work-up including
a clinical examination, anthropometric measurements,
laboratory tests and a liver US scan.
Laboratory determinations
Study population underwent fasting blood sampling to
assess blood glucose (FBG), glycosylated hemoglobin
(HbA1c), total cholesterol, HDL-cholesterol, triglycer-
ides, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), gamma-glutamyl transpeptidase
(gamma-GT), alkaline phosphatase, nitrogen and creati-
nine by standard laboratory methods. Insulin was
measured by radio-immuno-assay (ADVIA Insulin
Ready Pack 100, Bayer Diagnostics, Milan, Italy), with
intra- and inter-assay coefficients of variation < 5%.
Low-density lipoprotein (LDL) cholesterol value was
obtained using Friedwald formula. The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as previously described [21]. MS was defined
according to modified NCEP ATP-III criteria [22] and
diabetes mellitus according to ADA 2009 criteria [23].
NAFLD evaluation
Liver ultrasonography (US) scanning was performed to
assess the degree of steatosis. All US were performed by
the same operator who was unaware of the aims of the
study and blinded to laboratory values using an Esaote
Medica apparatus equipped with a convex 3,5 MHz
probe. Liver steatosis was scored semiquantitatively on a
s c a l eo f0 - 3 ;0 ,a b s e n t ;1 ,m i l d ;2 ,m o d e r a t e ;3 ,s e v e r e .
Steatosis was graded according to Saverymuttu et al.
[24] on the basis of abnormally intense, high level
echoes arising from the hepatic parenchyma, liver-kid-
ney difference in echo amplitude, echo penetration into
deep portion of the liver and clarity of liver blood vessel
structure.
We also evaluated the Fatty Liver Index (FLI), a clini-
cal and metabolic correlate of NAFLD, in both patients
and non-NAFLD subjects. FLI is expressed as a 0-100
range number; a value < 30 rules out and >60 rules in
the presence of hepatic steatosis with a sensibility and
specificity of 87% and 86%, though the following for-
mula: FLI = (e
0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge
(ggt) + 0.053*waist circumference - 15.745)/(1 + e
0.953*loge (trigly-
cerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference -
15.745) * 100 [25].
25(OH) vitamin D measurement
In order to assess the calcitriol balance in our popula-
tion, we measured serum 25(OH) vitamin D, the most
stable circulating form of this molecule [26,27]. Blood
samples were obtained in the same season and 25(OH)
vitamin D was measured by a validated colorimetric
method (LAISON, DiaSorin) on sera frozen immediately
after separation and stored at -25°C for few days.
Statistics
SPSS version 17 statistical package was used to perform
the analyses. Student’s T-test for continuous variables and
c
2 test for categorical variables were used to compare
mean values between two independent groups. Because
HOMA-IR, FBG, triglycerides, AST, ALT, GGT and alka-
line phosphatase were skewed, we used natural logarith-
mic transformations of these variables before performing
means comparison (Student’s T-test), ordinal and multi-
variate regression analyses. Logistic regression was used to
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metabolic parameters on the presence of NAFLD, consid-
ered as dichotomous variable. Ordinal regression was used
to detect the association between predictor variables and
presence and degree of NAFLD (0: absence, 1: mild, 2:
moderate, 3: severe). FLI and 25(OH) vitamin D were ana-
lyzed as continuous variables. A multiple liner regression
analysis was performed to investigate independent associa-
tion between FLI (dependent variable) and clinical and
biochemical parameters. The comparison of clinical/bio-
chemical characteristics among different 25(OH) vitamin
D quartiles was performed by means of ANOVA and
Kruskal-Wallis analyses, as appropriate. Data are shown as
mean ± standard deviation. For all the above, a p-value <
0.05 was considered statistically significant.
The study protocol was reviewed and approved by the
Ethics Commettee of Policlinico Umberto I, Sapienza
University of Rome and conducted in conformance with
the Helsinki Declaration. Written consent was obtained
from all patients before the study.
Results
Out of the 262 consecutive subjects who underwent
liver US examination, 162 (61.8%) were affected by
NAFLD (43.0% mild, 39.2% moderate and 17.8%
severe) and 100 were free from NAFLD or other liver
diseases.
NAFLD and non-NAFLD subjects differed significantly
in several parameters, such as BMI (p < 0.001), waist cir-
cumference (p < 0.001) HDL (p < 0.001) and triglycerides
(p < 0.001). Clinical and biochemical characteristics of
study population are summarized in Table 1.
NAFLD and 25(OH) vitamin D
Patients with NAFLD had reduced serum 25(OH) vita-
min D levels compared with subjects without NAFLD
who had mean values just above the threshold of 20 ng/
ml (50 nmol/l) for normal vitamin D status [28] (14.8 ±
9.2 vs 20.5 ± 9.7 ng/ml, p < 0.001, OR 0.95, IC 95%
0.92-0.98).
The association between NAFLD and low 25(OH)
vitamin D levels was independent from age, sex, trigly-
cerides, HDL and FBG in the multiple logistic regres-
sion analysis (p < 0.005) (Table 2) and is not affected by
BMI in a multivariate logistic model comprising sex,
age, 25(OH) vitamin D and BMI (25(OH) vitamin D:
OR 0.93, C.I. 0.88-0.99, p = 0.02; BMI OR 4.4, C.I. 2.2-
8.9, p < 0.001).
Table 1 Clinical and biochemical characteristics of study population.
Parameter NAFLD (n = 162) No NAFLD (n = 100) p-value
Age (years) 52.07 ± 8.18 49.81 ± 7.7 n.s.
Sex^ (M/F) 89/73 51/49 n.s.
BMI (kg/m
2) 31.36 ± 5.49 25.87 ± 5.1 < 0.001
Waist circumference (cm) 105.94 ± 12.68 90.26 ± 18.10 < 0.001
SBP (mmHg) 132.90 ± 14.63 120.12 ± 18.74 < 0.001
DBP (mHg) 81.20 ± 9.83 77.23 ± 7.93 0.005
HOMA-IR 10.42 ± 15.44 3.62 ± 2.89 < 0.001
FBG (mg/dl) 114.8 ± 27.9 100.4 ± 28.6 < 0.001
Total cholesterol (mg/dl) 195.76 ± 42.37 198.85 ± 40.18 n.s.
HDL-cholesterol (mg/dl) 46.76 ± 10.89 56.34 ± 12.29 < 0.001
LDL-cholesterol (mg/dl) 116.97 ± 43.39 119.41 ± 41.19 n.s.
Triglycerides (mg/dl) 172.5 ± 95.2 103.1 ± 47.6 < 0.001
AST (IU/l) 26.5 ± 15.4 18.9 ± 5.6 < 0.001
ALT (IU/l) 37.7 ± 24.6 20.4 ± 10 < 0.001
GGT (IU/l) 45.5 ± 71.2 20.3 ± 14.7 < 0.001
Alkaline phosphatase (IU/l) 73.3 ± 27.4 61.7 ± 20.9 0.02
25(OH) vitamin D (ng/ml) 14.8 ± 9.2 20.5 ± 9.7 < 0.001
FLI 71.66 ± 25.25 30.25 ± 28.93 < 0.001
MS^ (%/n) 73/118 23/23 < 0.001
T2D^ (%/n) 39/63 39/63 < 0.001
NAFLD degree I = 43%
II = 39.2%
III = 17.8%
Results are shown as mean ± SD. Student’s T test. ^Chi-square test applied. HOMA-IR, FBG, triglycerides, AST, ALT, GGT and alkaline phosphatase were considered
as log-values in the analysis.
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normal-weight subjects (n = 70, BMI< 25 kg/m
2) in which
the prevalence of NAFLD was 13.7%; also in this group of
normal-weight individuals those with NAFLD had serum
25(OH) vitamin D levels significantly reduced compared
with subjects without NAFLD (14.6 ± 9.7 vs 23.2 ± 8.9 ng/
ml, p = 0.01). Multivariate regression analysis performed
in this normal-weight population showed that the associa-
tion between NAFLD and vitamin D was independent
from sex, age, FBG, triglycerides and BMI (Table 3).
Moreover, we performed an ordinal regression analysis
that showed a significant association between NAFLD
scores, serum 25(OH) vitamin D levels, the components
of MS and the insulin resistance degree, measured by
means of HOMA-IR (Table 4).
After stratifying the study sample according to serum
25(OH) vitamin D quartiles, we observed an increased
prevalence of NAFLD, MS and its components in the
lowest 25(OH) vitamin D quartiles, whereas the preva-
lence of type 2 diabetes (T2D) was similar throughout
the quartiles of vitamin D. Table 5 shows clinical and
biochemical values of study population according with
25(OH) vitamin D quartiles and the results of inter-
groups trend test.
Interestingly, the lowest 25(OH) vitamin D quartile
showed an OR = 4.71 (CI 2.15-10.3, p < 0.001) for
NAFLD compared to the highest one.
FLI, fatty liver and 25(OH) vitamin D
NAFLD patients had significantly higher FLI compared to
non-NAFLD subjects (71.6 ± 25.2 vs 30.2 ± 28.9, p <
0.001) and the correlation between US detected NAFLD
and FLI was extremely tight, both when considering fatty
liver as dichotomous variable (r = 0.61, p < 0.001), and
when considering NAFLD severity scale (r = 0.66, p <
0.001). FLI inversely correlated with 25(OH) vitamin D
regardless sex, age and HOMA-IR (Unstandardized b
coefficient: -1.6, standardized b coefficient: -0.4, p < 0.007).
T2D and 25(OH) vitamin D
We also analyzed our study population according to the
presence of T2D. Patients affected by T2D had serum
25(OH) vitamin D levels similar to non diabetic patients
(17 ± 10.2 ng/ml vs 17.5 ± 8.8, p = n.s.); the logistic
regression analysis performed in the whole population
confirmed that vitamin D was not a determinant of dia-
betes (p = n.s.)
Discussion
This study demonstrates that subjects affected by
NAFLD have reduced serum 25(OH) vitamin D levels
compared to age and sex matched individuals without
NAFLD. This relationship is independent from the pre-
sence of T2D, MS and its individual components. Sub-
jects belonging to the lowest vitamin D quartile display
Table 2 Multiple logistic analysis.
Term Odds Ratio 95% C.I. Coefficient S. E. Z-Statistic P-Value
Sex 1.28 0.54 3.02 0.25 0.44 0.56 0.57
Age 1.04 0.99 1.09 0.04 0.02 1.56 0.12
FBG 1.01 0.99 1.03 0.01 0.01 1.66 0.09
HDL 0.99 0.96 1.02 -0.01 0.02 -0.57 0.57
Triglycerides 1.01 1.00 1.02 0.01 0.003 2.75 0.0059
Vitamin D 0.93 0.88 0.98 -0.07 0.02 -2.80 0.0051
CONSTANT * * * -3.14 1.99 -1.58 0.11
NAFLD dependent variable.
FBG, fasting blood glucose; HDL, high density lipoprotein
P-values < 0.05 were considered significant. Likelihood Ratio < 0.001.
Table 3 Multiple logistic regression analysis in subject with BMI< 25 Kg/m
2.
Term Odds Ratio 95% C.I. Coefficient S. E. Z-Statistic P-Value
Sex 1.53 0.69 3.37 0.43 0.40 1.06 0.29
Age 0.97 0.84 1.12 -0.03 0.07 -0.42 0.68
FBG 1.00 0.95 1.06 0.01 0.02 0.19 0.84
HDL 0.88 0.12 6.14 -0.13 0.99 -0.13 0.89
Triglycerides 0.99 0.97 1.02 -0.01 0.01 -0.48 0.63
Vitamin D 0.86 0.76 0.98 -0.15 0.06 -2.33 0.019
CONSTANT * * * -5.90 9.14 -0.64 0.52
NAFLD dependent variable.
P-values < 0.05 were considered significant.
FBG, fasting blood glucose; HDL, high density lipoprotein
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suggesting the presence of an overall increased cardio-
metabolic risk profile.
Previously, an association between low 25(OH) vita-
min D levels and the histological severity of NASH was
suggested by Targher et al. [29] in patients with chroni-
cally elevated liver enzymes and hepatic steatosis
detected by US, who underwent liver biopsy for sus-
pected steatohepatitis.
The present study was designed to investigate the rela-
tionship between fatty liver and hypovitaminosis D in a
cohort of subjects with different degrees of insulin-resis-
tance and no previously diagnosed liver disease, who
were well characterized with respect to medical history,
anthropometric measures and biochemical parameters.
NAFLD was assessed by liver US, which has been
demonstrated to have a sensitivity of 83% and a specifi-
city of 100% using histological criteria as gold standard
[24]. US is suitable for routine evaluation of fatty liver
in dysmetabolic patients, who, in most cases, do not get
progressive liver disease and can be well managed with-
out a need for liver biopsy, which cannot be performed
at large in patients with no significant or trivial liver dis-
ease, mainly for ethical reasons. Yet, in our series, sub-
jects had normal ALT and no clinical indication for
histological confirmation of NAFLD.
We also calculated the Fatty Liver Index (FLI), a sim-
ple and accurate predictor of hepatic steatosis in the
general population [25]. In our study cohort FLI tightly
correlated with the presence/degree of NAFLD detected
by US and the association between FLI and low vitamin
D concentration was independent from sex, age and
insulin resistance, quantified by means of HOMA-IR.
Vitamin D is known to be stored into the adipocytes
and serum 25(OH) vitamin D levels could be signifi-
cantly influenced by body composition. We did not
make direct measurements of body fatness but we mea-
sured waist circumference and BMI which are proxies
Table 5 Clinical-biochemical characteristics of study population according to serum 25(OH) vitamin D quartiles.
I Quartile
(n = 51)
II Quartile
(n = 66)
III Quartile
(n = 62)
IV Quartile
(n = 83)
P-value
Age (years) 55.93 ± 9.34 52.1 ± 10.7 52.2 ± 11.2 52.24 ± 9.45 n.s.
Sex° (M/F) 30/21 32/34 33/29 37/46 n.s.
BMI (kg/m
2) 30.99 ± 6.96 29.5 ± 5.8 27.04 ± 4 26.25 ± 4.38 < 0.001
Waist circumference (cm) 105.27 ± 16.82 103.6 ± 14.8 95.01 ± 19.2 91.08 ± 16.72 0.001
FBG (mg/dl) 111.5 ± 26.1 106.3 ± 23.7 107.7 ± 30.2 103.2 ± 31.1 n.s.
Total cholesterol (mg/dl) 206.05 ± 49.46 201.3 ± 41.1 197.5 ± 35.8 192.07 ± 40.95 n.s.
LDL-cholesterol (mg/dl) 122.73 ± 44.62 126.8 ± 37.5 123.6 ± 33.2 109.15 ± 46.07 n.s.
HDL-cholesterol (mg/dl) 51.88 ± 16.36 52.5 ± 12.7 52.5 ± 12.2 52.71 ± 13.82 n.s.
Triglycerides (mg/dl) 178.8 ± 98.7 124.8 ± 84.7 124.6 ± 75 115.6 ± 60.8 0.001
HOMA-IR 10.01 ± 7.58 5.15 ± 4.3 4.3 ± 9.8 5.32 ± 7.86 0.03
AST (IU/l) 21.1 ± 7.4 22.1 ± 11.1 25.6 ± 10.7 21.8 ± 11.01 n.s.
ALT (IU/l) 25.5 ± 14 28.8 ± 16.6 28.6 ± 21.7 26.7 ± 19.2 n.s.
FLI 71.77 ± 26.83 51.9 ± 33.3 45.02 ± 35.9 32.04 ± 29.79 < 0.001
NAFLD ° (%) 68.3 56.1 50 37.3 0.01
MS ° (%) 72.5 43.9 35.5 33.3 < 0.001
T2D ° (%) 36.2 22.7 24.2 25.3 n.s.
Results are shown as mean ± SD. ANOVA test applied. Kruskal-Wallis test applied. HOMA-IR, FBG, triglycerides, AST and ALT were considered as log-values in the
analysis. P-values < 0.05 were considered significant.
BMI, body mass index; FBG, fasting blood glucose; LDL, low-density lipoprotein; HDL, high density lipoprotein; HOMA-IR, homeostatis model assessment of insulin
resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FLI, fatty liver index; NAFLD, non-alcoholic fatty liver disease; MS, metabolic syndrome;
T2D, type 2 diabetes.
Table 4 Ordinal regression analysis of factors associated
with NAFLD scoring.
SE P-value
25(OH) vitamin D 0.01 0.001
Age 0.01 < 0.001
Sex 0.18 n.s.
BMI 0.03 < 0.001
Waist circumference 0.01 < 0.001
FBG 1.5 < 0.001
Total cholesterol 0.003 n.s.
HDL-cholesterol 0.01 < 0.001
LDL-cholesterol 0.003 n.s.
Triglycerides 0.7 < 0.001
HOMA-IR 0.8 < 0.001
Fasting insulin 0.6 < 0.001
SE, standard error of b. P-values < 0.05 were considered significant. HOMA-IR,
FBG and triglycerides, were considered as log-values in the analysis.
FBG, fasting blood glucose; HDL, high density lipoprotein; LDL, low-density
lipoprotein; HOMA-IR, homeostatis model assessment of insulin resistance.
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the possible confounding role of adiposity in determin-
ing serum 25(OH) vitamin D levels among patients with
BMI above normal limits [31], we performed a logistic
multivariate analysis also adjusting for BMI demonstrat-
ing that the association between NAFLD and 25(OH)
vitamin D persists after BMI adjustment. Furthermore,
we performed a sub-analysis in normal-weight patients
and controls and demonstrated that 25(OH) vitamin D
was significantly reduced in NAFLD individuals com-
pared to subjects without NAFLD, independently from
fatness and other possible confounding factors.
The role of vitamin D in the pathogenesis of hepatic
diseases is actually of great interest. In the liver, vitamin
D acts as an “immune-modulator” suppressing fibroblast
proliferation and collagen production [32,33].
Novel studies demonstrated that vitamin D deficiency
was associated with low rate of sustained virological
response (SVR) in patients affected by hepatitis C virus
(HCV) under interferon-alfa therapy [34,35]. Further-
more, a recent intervention trial showed that vitamin D
supplementation improves the probability of achieving a
SVR following antiviral treatment in patients with recur-
rent hepatitis C [36].
Serum vitamin D inversely associated with the pre-
sence of dysmetabolic conditions in our study as well as
in other published reports [5-7] and may play a role in
both NAFLD and cirrhosis outcomes though its anti-
inflammatory and insulin-sensitizing activities [37,38].
Moreover, vitamin D directly regulates the metabolism
of FFAs by means of its action on peroxisome prolifera-
tor-activated receptor gamma (PPAR-g) improving FFA-
induced insulin resistance in vitro.T h e r e f o r e ,u n d e r
condition of vitamin D deficiency, the increased FFAs
flow in the bloodstream may promote fat storage into
the liver and facilitate the development of NAFLD.
Our study has some limitations. First, the presence of
less common causes of liver disease, such as autoim-
mune hepatitis, hemochromatosis, or Wilson’s disease,
cannot be ruled out in our patients. Second, although
US is a practical approach commonly used to detect
liver steatosis, it is not the gold standard technique for
quantitative liver fat assessment. Another limitation of
this study relates to its cross-sectional design, that does
not allow to establish a causality nexus between low
serum 25(OH) vitamin D levels and the presence of
NAFLD.
Conclusions
In conclusion, we demonstrate a strong independent
association between low 25(OH) vitamin D levels and
NAFLD in a population of adults without signs of severe
liver damage even when the diagnosis of fatty liver is
based on routine US examination; this association is
independent from diabetes, lipid profile alterations and
insulin resistance and is partially hidden by fatness in
overweight subjects. Besides, an inverse correlation
between serum 25(OH) vitamin D levels and the degree
of NAFLD was observed, suggesting that vitamin D may
exert a dose-dependent effect on fat accumulation into
the hepatocytes.
Despite the cross-sectional design of this study, not
allowing to establish a causal nexus, overall our data
may suggest a significant contribution of hypovitamino-
s i sDi nt h ep a t h o g e n e s i so fl i v er steatosis. Intervention
trials are warranted to evaluate whether vitamin D sup-
plementation may be a means to prevent and/or treat
NAFLD.
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